GFM
BCRX icon

GF Fund Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

GF Fund Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.1K Buy
5,306
+598
+13% +$5.41K ﹤0.01% 382
2026
Q1 		$44.8K Buy
4,708
+571
+14% +$4.43K ﹤0.01% 414
2025
Q4 		$32.3K Sell
4,137
-379
-8% -$2.74K ﹤0.01% 450
2025
Q3 		$34.3K Sell
4,516
-787
-15% -$6.55K ﹤0.01% 432
2025
Q2 		$47.5K Hold
5,303
– – ﹤0.01% 418
2025
Q1 		$39.8K Buy
5,303
+954
+22% +$7.7K ﹤0.01% 441
2024
Q4 		$32.7K Buy
+4,349
New +$33K ﹤0.01% 429

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

GF Fund Management's BCRX Position: Q2 2026 in Review

GF Fund Management increased its BioCryst Pharmaceuticals (BCRX) stake by 13% in Q2 2026, buying an estimated $5.41K and bringing the position to 5,306 shares worth $53.1K. The position accounts for ﹤0.01% of the portfolio, ranked #382.

GF Fund Management first reported a position in BCRX in Q4 2024 and has held it in 7 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • GF Fund Management held 5,306 shares of BioCryst Pharmaceuticals worth $53.1K as of Q2 2026.
  • GF Fund Management bought 598 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $5.41K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #382 holding.
  • GF Fund Management first reported a position in BioCryst Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.